Literature DB >> 11733869

Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes.

B D'Agord Schaan1, S Lacchini, M C Bertoluci, M C Irigoyen, U F Machado, H Schmid.   

Abstract

Increased expression of transforming growth factor beta-1 (TGF-beta 1) and glucose transporter (GLUT1) has been implicated in the genesis of diabetic nephropathy. The aim of this study was to evaluate GLUT1 protein levels in the renal cortex of a rat model of diabetes as well as its relationship to urinary albumin and TGF-beta1. Streptozotocin-injected rats (n = 13) and controls (n = 13) were compared for their urinary albumin, and TGF-beta 1 and for renal cortical and medullar GLUT1 protein abundance. GLUT1 protein content was determined by optical densitometry after Western blotting using an anti-GLUT1 antibody; urinary albumin was measured using electroimmunoassay, urinary TGF-beta 1 using ELISA. Forty-five days of diabetes resulted in increased albuminuria (p < 0.05), urinary TGF-beta 1 (p < 0.05) and GLUT1 protein abundance (p < 0.05). There was a positive correlation between urinary TGF-beta 1 and plasma glucose levels (r = 0.65, p < 0.05) and albuminuria (r = 0.72, p < 0.05). We concluded that 45 days of diabetes result in incipient diabetic nephropathy and increased cortical GLUT1 protein abundance. We speculate that the higher cortical GLUT1 protein levels in diabetes may amplify the effects of hyperglycemia in determining higher intracellular glucose in mesangial cells, thereby contributing to diabetes-related kidney damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733869     DOI: 10.1055/s-2001-18683

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  14 in total

1.  Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney.

Authors:  Dilip K Deb; Riyue Bao; Yan Chun Li
Journal:  FASEB J       Date:  2017-02-01       Impact factor: 5.191

Review 2.  Glucose transporters in diabetic nephropathy.

Authors:  Frank C Brosius; Charles W Heilig
Journal:  Pediatr Nephrol       Date:  2005-02-17       Impact factor: 3.714

Review 3.  From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy.

Authors:  Ying Qian; Eva Feldman; Subramanian Pennathur; Matthias Kretzler; Frank C Brosius
Journal:  Diabetes       Date:  2008-06       Impact factor: 9.461

4.  GLUT1 enhances mTOR activity independently of TSC2 and AMPK.

Authors:  Carolyn L Buller; Charles W Heilig; Frank C Brosius
Journal:  Am J Physiol Renal Physiol       Date:  2011-05-25

5.  Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis.

Authors:  Youli Wang; Kathleen Heilig; Thomas Saunders; Andrew Minto; Dilip K Deb; Anthony Chang; Frank Brosius; Carmela Monteiro; Charles W Heilig
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-07

6.  Abnormalities in signaling pathways in diabetic nephropathy.

Authors:  Frank C Brosius; Charbel C Khoury; Carolyn L Buller; Sheldon Chen
Journal:  Expert Rev Endocrinol Metab       Date:  2010

Review 7.  The link between Glut-1 and hypertension in diabetic nephropathy.

Authors:  Luigi Gnudi; Leopoldo Raij
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 8.  Mesangial pathology in glomerular disease: targets for therapeutic intervention.

Authors:  Yogesh M Scindia; Umesh S Deshmukh; Harini Bagavant
Journal:  Adv Drug Deliv Rev       Date:  2010-09-07       Impact factor: 15.470

Review 9.  New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy.

Authors:  Frank C Brosius
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

Review 10.  Ion channels and transporters in diabetic kidney disease.

Authors:  Denisha Spires; Anna D Manis; Alexander Staruschenko
Journal:  Curr Top Membr       Date:  2019-02-18       Impact factor: 3.049

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.